CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
阴茎鳞状细胞癌中抗体偶联药物（TROP2 和 nectin-4）应答生物标志物与免疫微环境（NKG7、PD-L1 和 B7-H3）
英文原题：Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma.
查看英文原题
Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
靶向 TROP2 和 nectin-4 的治疗策略对晚期 pSCC 患者具有前景。
中文摘要
评估阴茎鳞状细胞癌（pSCC）中抗体药物偶联物疗效相关标志物（TROP2和nectin-4）及免疫微环境标志物（NKG7、PD-L1和B7-H3）的表达。
检索档案，纳入2000至2022年因pSCC接受阴茎切除术的患者。原发肿瘤进行B7-H3和NKG7免疫染色，转移灶标本进行TROP2和nectin-4免疫染色。原发肿瘤中的PD-L1、TROP2和nectin-4表达此前已有表征。采用H评分（0–300）量化表达，并评估生物标志物与TIL（肿瘤浸润淋巴细胞）、临床病理特征及结局参数的关联。
淋巴结转移灶中TROP2和nectin-4的H评分均高于原发肿瘤（均值分别为264.5比244.8，P=0.0003；170.6比146.7，P=0.05；33对配对标本）。在107例患者中，32.7%的原发肿瘤B7-H3 H评分大于0。34.8%的病例中，NKG7表达见于25%至50%的TIL。TIL密度与B7-H3、NKG7及PD-L1表达之间存在显著关联。
靶向TROP2和nectin-4的治疗策略对晚期pSCC患者具有前景。PD-L1、B7-H3和NKG7用于预测免疫调节治疗应答的潜力仍需进一步研究。
展开英文摘要原文
We aimed to assess the expression of biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma (pSCC).
Our archive was queried for patients who had a penectomy for pSCC between 2000 and 2022. Primary tumors were immunostained for B7-H3 and NKG7, while metastatic specimens were immunostained for TROP2 and nectin-4. Expression of PD-L1, TROP2, and nectin-4 in primary tumors was previously characterized. H-scores (0-300) were used to quantify expression. Associations between biomarkers, tumor-infiltrating lymphocytes (TILs), and clinicopathologic and outcome parameters were evaluated.
For both TROP2 and nectin-4, H-scores within the lymph node metastases were higher compared to those within the primary tumors (mean, 264.5 vs 244.8, P = .0003; mean, 170.6 vs 146.7, P = .05, respectively; 33 paired specimens). For B7-H3 (n = 107), 32.7% of the primary tumors had an H-score of more than 0. In 34.8% of the cases, NKG7 expression was observed in 25% to 50% of the TILs. A significant association was noted between TIL density, B7-H3, NKG7, and PD-L1 expression.
Therapeutic strategies targeting TROP2 and nectin-4 hold promise for patients with advanced pSCC. The potential of PD-L1, B7-H3, and NKG7 for predicting response to immunomodulatory treatment warrants further research.
论文信息
- 作者
- Tekin B、Cheville JC、Lucien F、McCarthy M、Dong H、Kopp KJ、Torell NR、Lavoie RR
- 单位
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.United States
- 期刊
- American journal of clinical pathology2025 Jun 3
- 原文标识
- PubMed 40327767 · DOI 10.1093/ajcp/aqaf022